Long-term safety and efficacy of DTX301 in adults with late-onset ornithine transcarbamylase (OTC) deficiency: A Phase 1/2 trial

被引：1

作者：

Thomas, Janet ^{[1
,2
]}

Tan, Wen-Hann ^{[3
]}

Khan, Aneal ^{[4
,5
]}

Konczal, Laura ^{[6
]}

Breilyn, Margo Sheck ^{[7
]}

Hualde, Leticia Ceberio ^{[8
]}

Couce, Marie Luz ^{[9
]}

Geberhiwot, Tarekegn ^{[10
]}

Guffon, Nathalie ^{[11
]}

Harding, Cary ^{[12
]}

Patra, Kaushik ^{[13
]}

Merritt, J. Lawrence, II ^{[13
]}

Crombez, Eric ^{[13
]}

机构：

[1] Univ CO, Sch Med, Aurora, CO USA

[2] Childrens Hosp Colorado, Aurora, CO USA

[3] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA

[4] MAGIC Clin Ltd, Calgary, AB, Canada

[5] Univ Calgary, Calgary, AB, Canada

[6] Univ Hosp Cleveland Med Ctr, Cleveland, OH USA

[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[8] Cruces Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Baracaldo, Spain

[9] Univ Santiago De Compostela, Santiago De Compostela, Spain

[10] Univ Birmingham, Birmingham, W Midlands, England

[11] HCL, Reference Ctr Inherited Metab Dis, Lyon, France

[12] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[13] Ultragenyx Pharmaceut Inc, Novato, CA USA

来源：

MOLECULAR GENETICS AND METABOLISM | 2024年 / 141卷 / 04期

关键词：

D O I：

10.1016/j.ymgme.2024.108266

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Poster # 0

引用

页数：2

共 50 条

[1] Long-Term Safety and Efficacy of DTX301 in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency: A Phase 1/2 Trial
Harding, Cary O.
Geberhiwot, Tarekegn
Couce, Maria Luz
Guffon, Nathalie
Hualde, Leticia Ceberio
Khan, Aneal
Konczal, Laura
Tan, Wen-Hann
Thomas, Janet
Breilyn, Margo
Patra, Kaushik
Merritt, J. Lawrence
Crombez, Eric
MOLECULAR THERAPY, 2023, 31 (04) : 69 - 69
[2] Safety and Efficacy of DTX301 in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency: A Phase 1/2 Trial
Harding, Cary O.
Geberhiwot, Tarekegn
Couce, Maria Luz
Tan, Wen-Hann
Khan, Aneal
Hualde, Leticia Ceberio
Diaz, George A.
Konczal, Laura
Thomas, Janet
Guffon, Nathalie
Lee, Connie
Puga, Ana
Crombez, Eric
MOLECULAR THERAPY, 2022, 30 (04) : 219 - 219
[3] Long-Term Safety and Urea Cycle Function Following a Phase 1/2 Trial of DTX301 in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency
Harding, Cary O.
Geberhiwot, Tarekegn
Couce, Maria Luz
Guffon, Nathalie
Tan, Wen-Hann
Hualde, Leticia Ceberio
Khan, Aneal
Konczal, Laura
Thomas, Janet A.
Breilyn, Margo Sheck
Zhang, Lin
Merritt, J. Lawrence
Crombez, Eric
MOLECULAR THERAPY, 2024, 32 (04) : 668 - 669
[4] Final safety and efficacy of a phase 1/2 trial of DTX301 in adults with late-onset ornithine transcarbamylase deficiency (OTCD)
Geberhiwot, T.
Harding, C. O.
Couce, M. L.
Tan, W-H
Khan, A.
Hualde, L. C.
Diaz, G. A.
Konczal, L.
Thomas, J.
Guffon, N.
Lee, C.
Puga, A. C.
Crombez, E.
HUMAN GENE THERAPY, 2022, 33 (23-24) : A9 - A9
[5] AAV8 gene therapy as a potential treatment for adults with late-onset ornithine transcarbamylase (OTC) deficiency: updated results from a phase 1/2 clinical trial
Geberhiwot, T.
Couce, M. L.
Hualde, L. C.
Harding, C. O.
Khan, A.
Diaz, G. A.
Tan, W.
Konczal, L.
Thomas, J.
Guffon, N.
Lee, C.
Puga, A. C.
Crombez, E.
HUMAN GENE THERAPY, 2021, 32 (19-20) : A9 - A9
[6] AAV8 Gene Therapy as a Potential Treatment in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency: Updated Results from a Phase 1/2 Clinical Trial
Harding, Cary O.
Luz Couce, Maria
Geberhiwot, Tarekegn
Tan, Wen-Hann
Khan, Aneal
Aldamiz-Echevarria, Luis
Diaz, George A.
Lee, Connie
Puga, Ana Cristina
Crombez, Eric
MOLECULAR THERAPY, 2021, 29 (04) : 17 - 17
[7] DESIGN OF A PHASE 3 STUDY OF AAV-MEDIATED GENE TRANSFER OF ORNITHINE TRANSCARBAMYLASE (OTC) IN PATIENTS WITH LATE-ONSET OTC DEFICIENCY
Konczal, Laura
Luz Couce, Marie
del Toro, Mireia
Langendonk, Janneke
Schulze, Andreas
Baker, Joshua
Burrow, T. Andrew
Lipshutz, Gerald S.
Longo, Nicola
Thomas, Janet
Merritt, J. Lawrence, II
MOLECULAR GENETICS AND METABOLISM, 2023, 138 (03) : 61 - 62
[8] Design of a Phase 3 study of AAV-mediated gene transfer of ornithine transcarbamylase (OTC) in patients with late-onset OTC deficiency
Konczal, Laura
Baker, Joshua
Wagenmakers, Margreet
Arnoux, Jean Baptiste
Burrow, T. Andrew
Couce, Marie Luz
del Toro, Mireia
Guelbert, Norberto
Kleppe, Soledad
Lipshutz, Gerald S.
Longo, Nicola
Matsumoto, Shiro
Schulze, Andreas
Thomas, Janet
Merritt, J. Lawrence, II
MOLECULAR GENETICS AND METABOLISM, 2024, 141 (04)
[9] A phase 1/2 clinical trial for AAV8-mediated liver-directed gene therapy in adults with late-onset OTC deficiency
Geberhiwot, T.
Aldamiz-Echevarria, L.
Couce, M. L.
Harding, C. O.
Khan, A.
Tan, W. H.
Lin, J.
Crombez, E.
Diaz, G. A.
HUMAN GENE THERAPY, 2018, 29 (12) : A59 - A59
[10] AAV8 Gene Therapy as a Potential Treatment in Adults with Late-Onset OTC Deficiency: Results from a Phase 1/2 Clinical Trial
Tan, Wen-Hann
Geberhiwot, Tarekegn
Couce, Maria Luz
Aldamiz-Echevarria, Luis
Diaz, George A.
Harding, Cary O.
Khan, Aneal
Lee, Connie
Puga, Ana Cristina
Crombez, Eric
MOLECULAR THERAPY, 2020, 28 (04) : 222 - 222

← 1 2 3 4 5 →